Old timer you could began your search around this time:

(2013)

"..... Pursuant to the Arrangement, Resverlogix intends to retain its research and development activities related to the development of compounds for applications with indications involving a therapeutic increase in Apolipoprotein A-1 ("Apo A-I"), including the clinical program related to RVX-208, a first in class small molecule for the treatment of atherosclerosis and it intends to spin-off all other research and development activities related to its epigenetic platform technology (the "Spin-Off Assets") to Newco. Pursuant to the Arrangement, Newco will also be issued royalty preferred shares in the capital of Resverlogix which will provide Newco with a dividend equal to 6 to 12% of "Net Apo Revenue" as described in the Circular. As part of the Arrangement, Resverlogix will transfer to Newco all of the indebtedness of RVX Therapeutics owing to Resverlogix. Resverlogix will also transfer between $5 and $10 million of cash to provide for the initial capitalization of Newco..... ."